Clinical Trial

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Study acronym: FiREBOLT
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2025-10-07; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-10-29
Trial Details
NCT Number NCT07213791
Lead Sponsor Eli Lilly and Company
Conditions Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
Enrollment 241 participants
Start Date 2025-10-22
Primary Completion 2028-07 (estimated)
Study Completion 2033-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-06